Immune Persistence and Safety Survey regarding Initial and Booster Vaccination of Monovalent Vaccine for SARS-CoV-2 Omicron Strain XBB.1.5 (Cohort Study) in Japa
Not Applicable
- Conditions
- COVID-19
- Registration Number
- JPRN-UMIN000052238
- Lead Sponsor
- Juntendo University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 3391
Inclusion Criteria
Not provided
Exclusion Criteria
Those who are inappropriate as the subject of the survey determined by the principal investigator
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety up to 4 weeks after initial or booster recipients of SARS-CoV-2 vaccine for XBB strain
- Secondary Outcome Measures
Name Time Method Breakthrough infection rate up to 12 months after the last SARS-CoV-2 vaccination Serious adverse events up to 12 months after vaccination (regardless of causality) Changes in COVID-19 antibody titer up to 12 months after vaccination (some of the survey subjects)